For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
07/25/14Amgen Announces 2014 Third Quarter DividendPrinter Friendly Version
07/24/14Amgen Announces Webcast of 2014 Second Quarter Financial ResultsPrinter Friendly Version
07/17/14Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving HemodialysisPrinter Friendly Version
07/01/14Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic LeukemiaPrinter Friendly Version
06/16/14Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung CancerPrinter Friendly Version
06/11/14Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of MedicinePrinter Friendly Version
06/09/14Amgen Appoints David W. Meline Executive Vice President and Chief Financial OfficerPrinter Friendly Version
06/06/14Amgen To Present At The Goldman Sachs Global Healthcare ConferencePrinter Friendly Version
06/02/14Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCOPrinter Friendly Version
06/01/14New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High CholesterolPrinter Friendly Version